Genmab — August 2019
-
Leading indicators går modsat https://www.conference-board.org/data/bcicountry.cfm?cid=1
-
1.378,50..Aktien forsætter med at danne base.
-
Lynge..."Basedannelse" sker ofte kortvarigt eller langvarigt i aktier i en sund uptrend. I dette tilfælde bevæger aktien sig lidt frem og tilbage under 1.389, hvilket har været højeste kurs i de seneste tre år.
-
Nogle af de korte investorer stiger af. Aktierne købes så af andre som både kan være korte, mellemlang og lange. At puste ud og få vejret giver luft til den næste spurt op ad bakken.
-
Vi er tæt på niveauet før rabat-nedturen i oktober 17. Og da der ikke ventes rabatter ved q3, og da 1. linje i us efterhånden må kunne ses på salget, er der vel lagt i kakkelovnen til en længe ventet optur i efteråret. Læg dertil Asclepios snart og cd3xcd20 senere.
-
!! Daratumumab synergizes with R-CHOP to reduce tumor burden in preclinical models of MCL and FL (...) In conclusion, these data demonstrate the value of the combination R-D-CHOP as a new
therapeutic strategy in MCL and tFL superior to the standard of care (R-CHOP) -
providing a strong rationale for examining its clinical efficacy in different scenarios, including
maintenance therapy after induction therapy, cases with anti-CD20 resistance, FL histologic
transformation, and as frontline in combination with the standard of care (CHOP/ R-CHOP) -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind